N
Novocardia
Building a network of America’s leading cardiologists to improve cardiovascular health across America
About Novocardia
Novocardia is a pioneering startup in the healthcare sector, specifically focusing on cardiovascular care. The company is dedicated to improving cardiac health across America by building a nationwide network of top cardiologists. Novocardia operates in the value-based care market, which means they focus on providing high-quality care while keeping costs reasonable. This approach results in better patient outcomes and higher satisfaction among both patients and clinicians.
The business primarily serves patients with cardiovascular conditions, aiming to deliver the right care at the right time and place. They achieve this through a combination of advanced technology and data analytics. Novocardia uses electronic health records (EHR) and payer claims data to track patient outcomes, healthcare utilization, and costs. This helps them to identify and address patient needs promptly.
One of Novocardia's key offerings is their Care Transitions Intervention, which ensures smooth transitions between different healthcare settings. This helps to prevent unnecessary hospitalizations and emergency room visits, thereby reducing healthcare costs. They also offer a Longitudinal Heart Failure Program, providing comprehensive support for patients with heart failure.
Novocardia's business model revolves around value-based care, where they get paid based on patient outcomes rather than the volume of services provided. This model incentivizes them to keep patients healthy and satisfied. They make money through partnerships with healthcare providers and payers, leveraging their proprietary technology and actuarial models to optimize care delivery and cost management.
In summary, Novocardia is revolutionizing cardiovascular care by combining a network of leading cardiologists with cutting-edge technology and a value-based care approach. This ensures that patients receive high-quality, timely care while keeping costs in check.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2023 | $0 | — | Cardiovascular Associates of America | ↗ |
| SERIES AOther financing | Jun 2021 | $54M | $215M | Deerfield | — |
Growth signals
Latest recorded traffic for Novocardia is 1.4K monthly website visits, up 0% over the last three months. Novocardia's team declined 87.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Deerfield
Other known investors1 additional known investor
Cardiovascular Associates of America
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novocardia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novocardia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







